TGA seeks input on MDMA, psilocybin downschedule

depression mental health anxiety population
The TGA has decided to seek further advice in relation to psilocybin and MDMA and their therapeutic use The TGA says this will include “an independent expert review into the therapeutic value, risks and benefits to public health outcomes for these substances as well as seeking additional advice from the Advisory Committee on Medicines Scheduling

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Drug-related deaths rising
Next ‘No confidence’ in pharmacist after misconduct